Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 7/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097691 | 0.99 | FOLH1 (0.56) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097720 | 0.99 | FOLH1 (0.56) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097666 | 0.99 | FOLH1 (0.56) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31314410 | 0.95 | FOLH1 (0.52) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL30463276 | 0.95 | FOLH1 (0.54) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097730 | 0.95 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097692 | 0.95 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097742 | 0.95 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097663 | 0.95 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL31097709 | 0.95 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12454771-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4556467-A2 | METHODS FOR ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12251674-B2 | Substrates, systems, and methods for array synthesis and biomolecular analysis | VIBRANT HOLDINGS, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3617219-B1 | METHODS FOR ARRAY SYNTHESIS | VIBRANT HOLDINGS LLC (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-118632859-A | Cyclic epitope tag | 生物技术欧洲股份公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240252516-A1 | COMBINATION BPH THERAPY WITH FEXAPOTIDE TRIFLUTATE, A 5-ARI, AND AN ALPHA BLOCKER | NYMOX CORPORATION | 2024-08-01 | — | — | US | disclosed |
| CN-110381984-B | Compositions and methods for improving sexual function | 尼莫克斯股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230294063-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS, LLC | 2023-09-21 | — | — | US | disclosed |
| US-11565231-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4003533-A1 | METHODS OF TREATING MULTIFOCAL CANCER | Nymox Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003387-A1 | FOCAL TREATMENT OF PROSTATE CANCER | Nymox Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3969112-A1 | METHOD OF TREATING LOWER URINARY TRACT SYMPTOMS WITH FEXAPOTIDE TRIFLUTATE | Nymox Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969030-A1 | METHOD OF ENHANCING THE THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN TREATING LUTS | Nymox Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230294063-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, IAPP, GIPR | FOLH1 644/4885NPY1R 60/4885NPY2R 70/4885 |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, CALCB, SPPL2B | FOLH1 341/4885NPY1R 71/4885NPY2R 50/4885 |
| US-11565231-B2 | Substrates, peptide arrays, and methods | VIP, IAPP, GIPR | FOLH1 644/4885NPY1R 60/4885NPY2R 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.